文献速递心外重症与机械循环支持

术前肾功能不全不影响左心室辅助装置植入的结局

Preoperative renal dysfunction does not affect outcomes of left ventricular assist device implantation.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-06-09

该单中心研究纳入2006至2015年因目的地治疗或移植前过渡植入耐久左心室辅助装置(LVAD)的238例患者,按术前肾小球滤过率(GFR)>60 mL/min与<60 mL/min或依赖透析分层。结果显示两组在1、3、6、12个月生存率相似,约半数术前肾功能不全者术后1年内肾功能恢复正常,结论为肾功能不全本身不应作为LVAD治疗的绝对禁忌证。

要点

  • 术前GFR降低者占56%(132/238),其中8%(18例)依赖透析。
  • 正常与降低GFR两组在1、3、6、12个月生存率相似(目的地治疗和移植前过渡均如此)。
  • 术前肾功能不全者中约半数在术后1年内GFR恢复至>60 mL/min。

核心结论

  • 经过良好选择的术前肾功能不全患者可接受LVAD植入并获得可接受的结局。
  • 约半数术前肾功能不全的LVAD接受者在术后第一年内恢复正常肾功能。
  • 肾功能不全本身不应作为LVAD治疗的绝对禁忌证。

研究设计与样本

  • 单中心研究,纳入2006年至2015年因目的地治疗(DT)或移植前过渡(BTT)植入LVAD的患者。
  • 共238例,其中DT占60%(n=142),BTT占40%(n=96)。
  • 按术前GFR分层:>60 mL/min versus <60 mL/min或依赖透析。
  • 主要结局为LVAD植入后总体生存率。

主要发现

  • 术前GFR降低者占56%(n=132),其中依赖透析者占8%(n=18)。
  • 正常与降低GFR两组匹配良好,仅降低GFR组冠状动脉疾病发生率更高(61% vs 48%;P = .04)。
  • 平均随访13.5 ± 17.0个月,DT和BTT队列中两组在LVAD植入后1、3、6、12个月的非校正和风险校正生存率均相似。
  • BTT患者中移植率两组相当(正常GFR组61% vs 降低GFR组53%;P = .43)。
  • 术后1年内,降低GFR患者中BTT队列有43%(n=17)、DT队列有57%(n=42)肾功能恢复至GFR >60 mL/min。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Selection criteria for durable left ventricular assist device (LVAD) implantation remain unclear. One such criterion is renal function. In this study we evaluated outcomes of LVAD implantation in patients with preoperative renal dysfunction. METHODS: Patients with implanted LVADs as destination therapy (DT) or bridge to transplantation (BTT) at a single institution between 2006 and 2015 were included. Primary stratification was according to pre-implantation glomerular filtration rate (GFR): >60 mL/min versus <60 mL/min or dialysis dependence. The primary outcome was post-LVAD implantation overall survival. RESULTS: Two hundred thirty-eight patients underwent LVAD implantation during the study period as DT (60%; n = 142) or BTT (40%; n = 96). Reduced GFR was present in 56% (n = 132), with 8% (n = 18) being dialysis-dependent. Normal versus reduced GFR cohorts were well matched except for a higher incidence of coronary artery disease in the patients with reduced GFR (61% vs 48%; P = .04). Mean follow-up was 13.5 ± 17.0 months. Unadjusted and risk-adjusted survival at 1, 3, 6, and 12 months after LVAD implantation were similar between the cohorts for DT and BTT. Rates of transplantation were comparable in BTT patients (61% normal vs 53% reduced GFR; P = .43). Recovery of renal function to a GFR >60 mL/min occurred in 43% (n = 17) and 57% (n = 42) of patients with reduced GFR in the BTT and DT cohorts, respectively, by 1 year post implantation. CONCLUSIONS: Well selected patients with preexisting renal dysfunction can undergo LVAD implantation with acceptable outcomes. Approximately half of LVAD recipients with preimplantation renal dysfunction will recover normal renal function within the first postoperative year. Renal dysfunction alone should not serve as an absolute contraindication to LVAD therapy.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kilic A, Chen CW, Gaffey AC, et al. Preoperative renal dysfunction does not affect outcomes of left ventricular assist device implantation. J Thorac Cardiovasc Surg. 2018. PMID: 30017440. doi:10.1016/j.jtcvs.2017.12.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。